BioWorld

June 26, 2002

View Archived Issues

BioCryst Reports Lead Flu Drug Fails In Phase III Against Placebo

BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study. (BioWorld Today) Read More

Celera Diagnostics, Abbott Align For In Vitro Molecular Diagnostics

Read More

Key To Hair Loss In Mouse, Man Traced To Key Keratin 17 Mutant Via Two Exotic Follicle Disorders

Read More

Geron Restructuring Leaves Focus On Product Development

Read More

Other News To Note

Read More

Odyssey Raises $15M In Series B To Fund Work In Drug Discovery

Read More